New in @JAMANetworkOpen: Phase 2 results for Dengue-mAb show the first proof of concept for an antiviral as a treatment for confirmed dengue patients seeking medical care. At 5–7mg/kg, it rapidly cut viremia and fever, with no related serious AEs.
jamanetwork.com/journals/jaman…
1/2
Swissinfo takes a closer look at the strategic collaboration between DNDi, @MedsforMalaria and @gardp_amr as the global health landscape changes.
🔗Read here:
We are proud to contribute to a new publication in the Journal of Translational Medicine on ICH E21 - guidance to improve the inclusion of pregnant and breastfeeding individuals in clinical trials and address evidence gaps in their care.
link.springer.com/epdf/10.1186/s…
